Research Paper Volume 12, Issue 10 pp 8893—8912

Figure 3. Overexpression of lncRNA-LOC645166 confers adriamycin tolerance to breast cancer cells. (A) RT–qPCR analysis of LOC645166 in 231 and MCF-7 cells transfected with Vector and lnc-LOC645166 for 48 h (n=3). (B) The effect of lnc-LOC645166 overexpression on the cell sensitivity to ADR of 231 and MCF-7 cells. (C, D) The effect of LOC645166 overexpression on the cell colony formation ability of 231 and MCF-7 cells under ADR treatment (231, 0.1μg/ml; MCF-7, 0.2μg/ml). (E, F) Flow cytometry analysis of Annexin V-stained 231 and MCF-7 cells transfected with Vector and lnc-LOC645166 upon adriamycin treatment (231, 0.1μg/ml; MCF-7, 0.2μg/ml) for 48 h (n=3).(G) Western blot analysis of the c-PARP,c-Caspase-3,p-STAT3 and STAT3 expression in 231and MCF-7 cells transfected with vector and lnc-LOC645166 upon adriamycin treatment (231, 0.1μg/ml; MCF-7, 0.2μg/ml) for 48 h (n=3). Data are shown as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.